The Minneapolis-based bank will issue the cards, and Mastercard will act as the network provider. American Express formerly ran the e-commerce giant's business credit card programs.
The Minneapolis-based bank will issue the cards, and Mastercard will act as the network provider. American Express formerly ran the e-commerce giant's business credit card programs.
Onconetix ( ONCO ) said on Tuesday it appointed David White as CEO, effective March 18, 2026, and named Sammy Dorf to its Board of Directors and audit committee, effective March 19, 2026. The company said outgoing interim CEO Karina Fedasz will continue to serve as interim CFO. White brings more than 30 years of executive leadership and board experience, having served in roles spanning CEO, CFO, a...
Onconetix ( ONCO ) said on Tuesday it appointed David White as CEO, effective March 18, 2026, and named Sammy Dorf to its Board of Directors and audit committee, effective March 19, 2026. The company said outgoing interim CEO Karina Fedasz will continue to serve as interim CFO. White brings more than 30 years of executive leadership and board experience, having served in roles spanning CEO, CFO, and COO across transportation, healthcare, and manufacturing, and currently serves as an independent director at Art's Way Manufacturing. Dorf is an entrepreneur, investor, and experienced public company director who co-founded Verano Holdings in 2015 and helped lead its expansion and public listing in 2021 and currently serves on the boards of SRx Health Solutions, where he is co-chair of the governance committee and a member of the audit committee, and Cube Exchange. Shares -19.07% More on Oncology Medical Onconetix, Inc. (ONCO) M&A Call Transcript Onconetix announces 1-for-5 reverse stock split Realbotix announces the sale of subsidiary to Onconetix Financial information for Oncology Medical
Stock index futures were higher on Tuesday as investors prepared for a busy session of corporate news and earnings. Here are the four stocks to watch on the day: Nike ( NKE ) shares will be in focus as the athletic apparel giant reports fiscal third-quarter results after the close. Wall Street analysts are expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year’s ma...
Stock index futures were higher on Tuesday as investors prepared for a busy session of corporate news and earnings. Here are the four stocks to watch on the day: Nike ( NKE ) shares will be in focus as the athletic apparel giant reports fiscal third-quarter results after the close. Wall Street analysts are expecting revenue of $11.2 billion and earnings per share of $0.28, down from last year’s mark of $0.54. Investors will be watching closely for updates on current demand trends, particularly in China, as well as the outlook for margins amid new headwinds. Novo Nordisk ( NVO ) slipped 0.14% in premarket trading after announcing a first-of-its-kind subscription program for its weight loss therapy Wegovy. The Danish drugmaker said the program will be available on telehealth platforms including LifeMD and Hims & Hers, with cash-paying patients able to choose 3-, 6-, or 12-month subscriptions of Wegovy injection and Wegovy pill starting March 31. Longer subscription periods will generate lower monthly pricing, the company said. Marvell Technology ( MRVL ) jumped more than 10% in premarket trading after Nvidia announced a $2 billion investment in the company. The two firms also unveiled a strategic partnership to connect Marvell to the Nvidia AI factory and AI-RAN ecosystem through Nvidia’s NVLink Fusion. Under the agreement , Marvell will provide custom AI accelerators and NVLink Fusion-compatible scale-up networking. Eli Lilly ( LLY ) gained 0.86% before the opening bell after announcing a definitive agreement to acquire Centessa Pharmaceuticals, a clinical-stage company developing treatments for excessive daytime sleepiness and other neurological conditions. Under the terms of the deal, Lilly will purchase all outstanding and future shares of Centessa, including its American Depositary Shares, for $38.00 per share in cash. More related stories Marvell Technology: More Visibility, More Design Wins, And More Upside Potential Novo Nordisk: Why I Still Find It An Interes...
(RTTNews) - Spice maker McCormick & Co. Inc. (MKC) announced Tuesday its agreement to combine with consumer goods major Unilever Plc.'s (UL, ULVR.L) Foods business excluding India and other excluded businesses. In the transaction, Unilever will receive $15.7 billion in cash, and
(RTTNews) - Spice maker McCormick & Co. Inc. (MKC) announced Tuesday its agreement to combine with consumer goods major Unilever Plc.'s (UL, ULVR.L) Foods business excluding India and other excluded businesses. In the transaction, Unilever will receive $15.7 billion in cash, and
Caribou Biosciences ( CRBU ) added ~9% in the premarket on Tuesday after the company announced that the U.S. FDA issued the Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell therapy, CB-011. An allogeneic anti-BCMA CAR-T cell therapy, CB-011, is currently undergoing a Phase 1 trial called CaMMouflage for adults with relapsed or refractory multiple myeloma. Berkeley, Cali...
Caribou Biosciences ( CRBU ) added ~9% in the premarket on Tuesday after the company announced that the U.S. FDA issued the Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell therapy, CB-011. An allogeneic anti-BCMA CAR-T cell therapy, CB-011, is currently undergoing a Phase 1 trial called CaMMouflage for adults with relapsed or refractory multiple myeloma. Berkeley, California-based Caribou ( CRBU ) noted that the FDA's decision was based on previously disclosed data from CaMMouflage, which indicated a 92% overall response rate in a review of 12 BCMA-naïve patients with r/r MM. The FDA’s RMAT designation aims to expedite the development and review of regenerative medicines such as cell therapies targeted at serious or life-threatening conditions. Developers can receive intensive regulatory guidance and be eligible for the FDA’s priority and rolling reviews for RMAT-designated drugs. They can even secure potential accelerated approvals if those treatments meet the required clinical standards. More on Caribou Bioscience Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value Caribou Biosciences, Inc. (CRBU) Presents at Leerink Global Healthcare Conference 2026 Transcript Caribou Biosciences, Inc. (CRBU) Presents at 2026 Tandem Meetings of ASTCT and CIBMTR - Slideshow Caribou Bioscience GAAP EPS of -$0.28 beats by $0.04, revenue of $3.94M beats by $1.98M Caribou Biosciences a new buy at Clear Street on CAR-T pipeline
Kenon ( KEN ) declares $3.85/share annual dividend . Forward yield 4.82% Payable April 20; for shareholders of record April 13; ex-div April 13. See KEN Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kenon Dividend scorecard for Kenon Financial information for Kenon
Kenon ( KEN ) declares $3.85/share annual dividend . Forward yield 4.82% Payable April 20; for shareholders of record April 13; ex-div April 13. See KEN Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kenon Dividend scorecard for Kenon Financial information for Kenon